In cancer care, accurate tools for predicting whether a tumour will metastasise can help patients receive the most appropriate treatments. But...
Vous n'êtes pas connecté
- ONCOLOGYNEWS.COM.AU - A La Une - 23/Jun 19:22
Racial differences in tumour collagen structure may impact cancer prognosis
In cancer care, accurate tools for predicting whether a tumour will metastasise can help patients receive the most appropriate treatments. But existing prediction methods don’t always work equally well for everyone. In particular, Black patients with breast or colon cancer often experience worse outcomes than White patients, despite receiving similar care. A new study from [...]
Articles similaires
Could AI Understand Your Tumour Better Than a Doctor?
medindia.net - 27/Jun 02:10
New AI tool, maps cancer cell diversity into five key types, unlocking the potential for personalized treatment and improved outcomes in breast...
Scotland’s cancer waiting times worst on record
news.stv.tv - 24/Jun 11:40
The number of patients receiving cancer treatments on time and within targets has hit its lowest point since records began in 2012.
‘People could be dying as a result of later cancer diagnoses’, MSP admits
news.stv.tv - 24/Jun 17:29
The number of patients receiving cancer treatments on time and within targets has hit its lowest point since records began in 2012.
‘People could be dying as a result of later cancer diagnoses’, minister admits
news.stv.tv - 24/Jun 17:29
The number of patients receiving cancer treatments on time and within targets has hit its lowest point since records began in 2012.
Scorpion venom offers new hope for breast cancer patients: Study
times of india - 24/Jun 12:18
Brazilian scientists have identified a molecule, BamazScplp1, in Amazonian scorpion venom that effectively kills breast cancer cells in early tests....
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market to Grow to USD 92.9M by 2035
wn.com - 24/Jun 07:32
The ESR1 mutated metastatic breast cancer diagnostics market is valued at USD 64.61 million in 2025 and is slated to reach USD 92.92 million by 2035,...
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market to Grow to USD 92.9M by 2035
wn.com - 24/Jun 07:32
The ESR1 mutated metastatic breast cancer diagnostics market is valued at USD 64.61 million in 2025 and is slated to reach USD 92.92 million by 2035,...
Cell therapy improves overall survival of patients with colorectal cancer
oncologynews.com.au - 15:56
Colorectal cancer (CRC) is the second most common cause of death from cancer in the United States (US) and the most prevalent malignant tumour...
Cell therapy improves overall survival of patients with colorectal cancer
oncologynews.com.au - 15:56
Colorectal cancer (CRC) is the second most common cause of death from cancer in the United States (US) and the most prevalent malignant tumour...
Les derniers communiqués
-
Aucun élément